Ongoing, recruitingTherapeutic confirmatory (Phase III)Interventional

A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer (KEYFORM-007)

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic confirmatory (Phase III)

Sponsor

Merck Sharp & Dohme LLC

Enrolment target

102

Start

21 May 2024

Overall Survival (OS)

Age 18 Years to any · Sex: All

Always speak to your GP or specialist before deciding to take part in a study.